$SAGE
Sage Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024118256 Filed on October 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $11.87M
YoY Change 337.08%
Cost Of Revenue $5.278M
YoY Change 486.44%
Gross Profit $6.593M
YoY Change 266.28%
Gross Profit Margin 55.54%
Selling, General & Admin $53.22M
YoY Change -31.89%
% of Gross Profit 807.2%
Research & Development $54.58M
YoY Change -46.45%
% of Gross Profit 827.79%
Depreciation & Amortization $255.0K
YoY Change -15.0%
% of Gross Profit 3.87%
Operating Expenses $113.1M
YoY Change -47.3%
Operating Profit -$101.2M
YoY Change -52.23%
Interest Expense $7.642M
YoY Change -25.62%
% of Operating Profit
Other Income/Expense, Net $9.000K
YoY Change -116.36%
Pretax Income -$93.55M
YoY Change -53.6%
Income Tax
% Of Pretax Income
Net Earnings -$93.55M
YoY Change -53.6%
Net Earnings / Revenue -788.06%
Basic Earnings Per Share -$1.53
Diluted Earnings Per Share -$1.53
COMMON SHARES
Basic Shares Outstanding 61.17M 61.05M
Diluted Shares Outstanding 61.12M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $569.2M
YoY Change -35.03%
Cash & Equivalents $99.63M
Short-Term Investments $469.5M
Other Short-Term Assets $17.76M
YoY Change -48.81%
Inventory
Prepaid Expenses
Receivables $14.87M
Other Receivables $0.00
Total Short-Term Assets $605.0M
YoY Change -35.18%
LONG-TERM ASSETS
Property, Plant & Equipment $1.019M
YoY Change -58.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.175M
YoY Change -21.51%
Total Long-Term Assets $17.45M
YoY Change 6.42%
TOTAL ASSETS
Total Short-Term Assets $605.0M
Total Long-Term Assets $17.45M
Total Assets $622.4M
YoY Change -34.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.126M
YoY Change -36.01%
Accrued Expenses $53.20M
YoY Change -53.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.41M
YoY Change -54.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $10.19M
YoY Change
Total Long-Term Liabilities $10.19M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $60.41M
Total Long-Term Liabilities $10.19M
Total Liabilities $70.60M
YoY Change -46.92%
SHAREHOLDERS EQUITY
Retained Earnings -$2.875B
YoY Change 13.31%
Common Stock $3.426B
YoY Change 2.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $551.8M
YoY Change
Total Liabilities & Shareholders Equity $622.4M
YoY Change -34.46%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$93.55M
YoY Change -53.6%
Depreciation, Depletion And Amortization $255.0K
YoY Change -15.0%
Cash From Operating Activities -$82.36M
YoY Change -39.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $81.05M
YoY Change -49.56%
Cash From Investing Activities $81.05M
YoY Change -49.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.037M
YoY Change -62.96%
NET CHANGE
Cash From Operating Activities -82.36M
Cash From Investing Activities 81.05M
Cash From Financing Activities 1.037M
Net Change In Cash -274.0K
YoY Change -101.0%
FREE CASH FLOW
Cash From Operating Activities -$82.36M
Capital Expenditures $0.00
Free Cash Flow -$82.36M
YoY Change -39.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001597553
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36544
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4486580
dei Entity Address Address Line1
EntityAddressAddressLine1
55 Cambridge Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SAGE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 us-gaap Accounts Receivable After Allowance For Credit Loss Current Related Party Type Extensible Enumeration
AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36544
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4486580
dei Entity Address Address Line1
EntityAddressAddressLine1
55 Cambridge Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
299-8380
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SAGE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61173263
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99627000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70992000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
469527000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
682192000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19630000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
31825000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14871000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
83009000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1332000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1332000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
604987000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
869350000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1019000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1921000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11251000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4458000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5175000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6548000
CY2024Q3 us-gaap Assets
Assets
622432000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10318000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53197000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67264000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
83000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5165000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
60406000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61173263
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99627000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70992000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
469527000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
682192000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19630000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
31825000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14871000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
83009000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1332000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1332000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
604987000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
869350000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1019000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1921000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11251000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4458000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5175000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6548000
CY2024Q3 us-gaap Assets
Assets
622432000
CY2023Q4 us-gaap Assets
Assets
882277000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7126000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10318000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53197000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67264000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
83000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5165000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
60406000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82747000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10191000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q3 us-gaap Liabilities
Liabilities
70597000
CY2023Q4 us-gaap Liabilities
Liabilities
82747000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82747000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10191000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q3 us-gaap Liabilities
Liabilities
70597000
CY2023Q4 us-gaap Liabilities
Liabilities
82747000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61176296
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60046676
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61173263
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60043643
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3425875000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3370397000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2874547000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2569659000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
901000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-814000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
551835000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
799530000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
622432000
CY2023Q3 us-gaap Revenues
Revenues
2716000
us-gaap Revenues
Revenues
28427000
us-gaap Revenues
Revenues
8483000
CY2024Q3 sage Cost Of Revenues
CostOfRevenues
5278000
CY2023Q3 sage Cost Of Revenues
CostOfRevenues
905000
sage Cost Of Revenues
CostOfRevenues
7955000
sage Cost Of Revenues
CostOfRevenues
1339000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54576000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101919000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
188873000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61176296
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60046676
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61173263
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60043643
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3425875000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3370397000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2874547000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2569659000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
901000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-814000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
551835000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
799530000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
622432000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
882277000
CY2024Q3 us-gaap Revenues
Revenues
11871000
CY2023Q3 us-gaap Revenues
Revenues
2716000
us-gaap Revenues
Revenues
28427000
us-gaap Revenues
Revenues
8483000
CY2024Q3 sage Cost Of Revenues
CostOfRevenues
5278000
CY2023Q3 sage Cost Of Revenues
CostOfRevenues
905000
sage Cost Of Revenues
CostOfRevenues
7955000
sage Cost Of Revenues
CostOfRevenues
1339000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54576000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101919000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
188873000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
291905000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53219000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
78142000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
161775000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
219415000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
33599000
us-gaap Restructuring Charges
RestructuringCharges
33599000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
113073000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
214565000
us-gaap Operating Expenses
OperatingExpenses
358603000
us-gaap Operating Expenses
OperatingExpenses
546258000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-101202000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-211849000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
291905000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53219000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
78142000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
161775000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
219415000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
33599000
us-gaap Restructuring Charges
RestructuringCharges
33599000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
113073000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
214565000
us-gaap Operating Expenses
OperatingExpenses
358603000
us-gaap Operating Expenses
OperatingExpenses
546258000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-101202000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-211849000
us-gaap Operating Income Loss
OperatingIncomeLoss
-330176000
us-gaap Operating Income Loss
OperatingIncomeLoss
-537775000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7642000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10274000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25277000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
29276000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-284000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
us-gaap Net Income Loss
NetIncomeLoss
-304888000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61116524
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61116524
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59912378
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59912378
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60598909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60598909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59786254
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
us-gaap Net Income Loss
NetIncomeLoss
-304888000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1592000
us-gaap Operating Income Loss
OperatingIncomeLoss
-330176000
us-gaap Operating Income Loss
OperatingIncomeLoss
-537775000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7642000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10274000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25277000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
29276000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-284000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
us-gaap Net Income Loss
NetIncomeLoss
-304888000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61116524
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61116524
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59912378
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59912378
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60598909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60598909
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59786254
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59786254
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
us-gaap Net Income Loss
NetIncomeLoss
-304888000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1592000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1715000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6471000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91959000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-199721000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-303173000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-502312000
us-gaap Profit Loss
ProfitLoss
-304888000
us-gaap Profit Loss
ProfitLoss
-508783000
us-gaap Share Based Compensation
ShareBasedCompensation
45072000
us-gaap Share Based Compensation
ShareBasedCompensation
60422000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
186000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
71000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
5538000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1715000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6471000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91959000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-199721000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-303173000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-502312000
us-gaap Profit Loss
ProfitLoss
-304888000
us-gaap Share Based Compensation
ShareBasedCompensation
60422000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
71000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
5538000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
12521000
us-gaap Depreciation
Depreciation
902000
us-gaap Depreciation
Depreciation
984000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12195000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16121000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-68138000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
8853000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2873000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1823000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-4679000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-4506000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-5082000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-676000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
149000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-4491000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3192000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7677000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-15756000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
41796000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-200634000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-421066000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
582357000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
861231000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
362253000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
459714000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
665000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
220104000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
400852000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
sage Proceeds From Public Offerings Of Common Stock Net Of Commissions And Underwriting Discounts
ProceedsFromPublicOfferingsOfCommonStockNetOfCommissionsAndUnderwritingDiscounts
8164000
sage Proceeds From Public Offerings Of Common Stock Net Of Commissions And Underwriting Discounts
ProceedsFromPublicOfferingsOfCommonStockNetOfCommissionsAndUnderwritingDiscounts
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
402000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
641000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10665000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6289000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
12521000
us-gaap Depreciation
Depreciation
902000
us-gaap Depreciation
Depreciation
984000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16121000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-68138000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
8853000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-4679000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-4506000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-5082000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-676000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
149000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7677000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-15756000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
41796000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-200634000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-421066000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
582357000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
861231000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
362253000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
459714000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
665000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
220104000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
400852000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3020000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6930000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
sage Proceeds From Public Offerings Of Common Stock Net Of Commissions And Underwriting Discounts
ProceedsFromPublicOfferingsOfCommonStockNetOfCommissionsAndUnderwritingDiscounts
8164000
sage Proceeds From Public Offerings Of Common Stock Net Of Commissions And Underwriting Discounts
ProceedsFromPublicOfferingsOfCommonStockNetOfCommissionsAndUnderwritingDiscounts
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
402000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
641000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10665000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6289000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30135000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13925000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72324000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
163969000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102459000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150044000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11472000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2863000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19568000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5118000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-629000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30135000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13925000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
72324000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
163969000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
102459000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150044000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11472000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2863000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19568000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5118000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-629000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-146828000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1133129000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
855000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11281000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-556000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-8000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
984376000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3656000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28352000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1909000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
816659000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
799530000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1507000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13170000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
27000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-2000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-108483000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
705801000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16947000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8047000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
96000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-102854000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
628062000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2182000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13949000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1592000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-146828000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1133129000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
855000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11281000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-556000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
984376000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3656000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28352000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1909000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
816659000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
799530000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1507000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13170000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
27000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-2000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-108483000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
705801000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16947000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8047000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
96000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-102854000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
628062000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2182000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13949000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1592000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-399000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
551835000
CY2024Q3 sage Incremental Cost Of Impairment Of Intangible Assets And Excess Inventory Write Off
IncrementalCostOfImpairmentOfIntangibleAssetsAndExcessInventoryWriteOff
3600000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-399000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
551835000
CY2024Q3 sage Incremental Cost Of Impairment Of Intangible Assets And Excess Inventory Write Off
IncrementalCostOfImpairmentOfIntangibleAssetsAndExcessInventoryWriteOff
3600000
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period</span><span style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period</span><span style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
98306000
CY2024Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
469527000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
567833000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
68547000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
682192000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
750739000
CY2024Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2023Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
468626000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
956000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
469527000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
683006000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
437000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1251000
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
98306000
CY2024Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
469527000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
567833000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
68547000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
682192000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
750739000
CY2024Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2023Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
468626000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
956000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
469527000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
683006000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
437000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1251000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
682192000
CY2024Q3 sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
CY2023Q3 sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
47550000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
34000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
34096000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
21000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
81646000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
55000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
343373000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
611000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
123121000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
640000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
466494000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1251000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
682192000
CY2024Q3 sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
CY2023Q3 sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
sage Accrued Interest Receivable Written Off
AccruedInterestReceivableWrittenOff
0
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
47550000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
34000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
34096000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
21000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
81646000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
55000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
343373000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
611000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
123121000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
640000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
466494000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1251000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q3 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
26754000
CY2023Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
26040000
CY2024Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
152000
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
10589000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17002000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21339000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8918000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8589000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
371000
CY2024Q3 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
26754000
CY2023Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
26040000
CY2024Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
152000
CY2023Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
10589000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17002000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21339000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8918000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8589000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
371000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
707000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53197000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67264000
CY2024Q3 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1292000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2461000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2976000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3059000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3144000
CY2024Q3 sage Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
3773000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14121000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3847000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10274000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
707000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53197000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67264000
CY2024Q3 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1292000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2461000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2976000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3059000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3144000
CY2024Q3 sage Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
3773000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14121000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3847000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10274000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
3033
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
3033
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
33800000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14207000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28691000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45072000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60422000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
33800000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14207000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28691000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45072000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60422000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14207000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28691000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45072000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60422000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.27
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
us-gaap Net Income Loss
NetIncomeLoss
-304888000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61116524
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61116524
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59912378
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59912378
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60598909
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60598909
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14207000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28691000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45072000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60422000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.27
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-93551000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-201630000
us-gaap Net Income Loss
NetIncomeLoss
-304888000
us-gaap Net Income Loss
NetIncomeLoss
-508783000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61116524
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61116524
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59912378
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59912378
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60598909
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60598909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59786254
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59786254
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.51
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423915
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8195915
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423915
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
32800000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59786254
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59786254
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.37
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.51
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8195915
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423915
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8195915
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9423915
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.40
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
32800000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
10589000
us-gaap Restructuring Charges
RestructuringCharges
597000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
10589000
us-gaap Restructuring Charges
RestructuringCharges
597000
us-gaap Payments For Restructuring
PaymentsForRestructuring
9840000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
152000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
us-gaap Payments For Restructuring
PaymentsForRestructuring
9840000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
152000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-118256-index-headers.html Edgar Link pending
0000950170-24-118256-index.html Edgar Link pending
0000950170-24-118256.txt Edgar Link pending
0000950170-24-118256-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img94128167_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-20240930.htm Edgar Link pending
sage-20240930.xsd Edgar Link pending
sage-ex31_1.htm Edgar Link pending
sage-ex31_2.htm Edgar Link pending
sage-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
sage-20240930_htm.xml Edgar Link completed